Advertisement Pharmaceutical Business review - Page 699 of 5261 -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
February 18, 2026

J&J’s Rybrevant Faspro gains FDA approval for new dosing in NSCLC

Johnson & Johnson (J&J) has received the US Food and Drug Administration (FDA) approval for a new monthly dosing schedule for the combination therapy Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) to treat patients with advanced, epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC).

Continue
The PALOMA-2 study showed monthly Rybrevant Faspro with Lazcluze achieved high response in untreated advanced EGFR-mutated NSCLC. Credit: Arif biswas/Shutterstock.com.
February 18, 2026

Evogene and QUT partner on AI-based cancer therapies

Evogene’s ChemPass AI platform will generate and prioritise chemical leads with drug-like, strong inhibitory properties. Credit: Gorodenkoff / Shutterstock.com.
February 17, 2026

ExCellThera secures German NUB Status 1 listing for Zemcelpro

Over 120 patients with haematologic malignancies took part in clinical trials across Canada, Europe, and the US. Credit: Anamaria Mejia / Shutterstock.com.

Contracts

January 23, 2025

Kamada to supply immune globulin products in Latin America

KAMRAB must be administered alongside a complete rabies vaccine regimen. Credit: Nappy on Unsplash.

Bavarian Nordic secures $156.8m US vaccine deal

Boehringer Ingelheim receives EC conditional marketing approval for spesolimab

Marinus Pharmaceuticals signs collaboration agreement with Tenacia Biotechnology

Deals

Deals January 20, 2025

Fermion and Simcere to partner on development of pain treatment drug

Pharmaceutical Business Review

WuXi Biologics and Sino Biopharm collaborate on monoclonal antibody discovery

Merck enhances ophthalmology portfolio with EyeBio acquisition

Biocon signs licensing and supply deal for diabetes drug in Brazil

Popular

  1. Teijin and Aska Pharmaceutical agree for gynaecological drug development
  2. Immunic secures $400m fund to support commercial-stage development
  3. Ampersand Capital acquires Purna Pharmaceuticals
  4. Amgen receives EC approval for Uplizna in generalised myasthenia gravis
  5. Citius Oncology and Uniphar sign European distribution deal for Lymphir

PRESS RELEASES

SCHOTT Pharma and SHL Medical Enhance Home-Based Large-Volume Injections for Patients
SCHOTT Pharma and SHL Medical Enhance Home-Based Large-Volume Injections for Patients
SCHOTT Pharma Launches Ready-to-Use Polymer Cartridge
SCHOTT Pharma Launches Ready-to-Use Polymer Cartridge
Accelerating Self-Administration and Homecare: SCHOTT Pharma Launches Large-Volume Prefillable Glass Syringe
Accelerating Self-Administration and Homecare: SCHOTT Pharma Launches Large-Volume Prefillable Glass Syringe
Pharmaceutical Business Review
Christian Mias to Succeed Andreas Reisse as CEO of SCHOTT Pharma
Pharmaceutical Business Review
LTS completes acquisition of Renaissance Lakewood, expanding global CDMO capabilities

Suppliers

Whitepapers

Smoothly Through the Production Process: EVERIC™ Strong/Smooth Test
Smoothly Through the Production Process: EVERIC™ Strong/Smooth Test
Strengths and Weaknesses of Different Prefilled Syringes for Injections in Hospitals: A Case Study by Niklas Niederwieser and Patrick Gallagher SCHOTT AG
Strengths and Weaknesses of Different Prefilled Syringes for Injections in Hospitals: A Case Study by Niklas Niederwieser and Patrick Gallagher SCHOTT AG
Tracking the Cracking: How to Optimise Pharma Fill-and-Finish Processes by Use of Strength Testing and Fractography
Tracking the Cracking: How to Optimise Pharma Fill-and-Finish Processes by Use of Strength Testing and Fractography